Transgenic News and Research

RSS

Link between diabetes and obesity

Scientists at Washington University School of Medicine in St. Louis used genetically modified mice to uncover a potentially important link between diabetes and obesity.

15 Feb 2005

Angiogenesis inhibitor molecules defend against the development and spread of cancer

Research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) helps explain how a group of angiogenesis inhibitor molecules serve as an important defense mechanism against the development and spread of cancer, offering key insights into why cancerous tumors grow at different rates among different individuals.

15 Feb 2005

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B Virus (HBV), an acute sometimes fatal form of viral hepatitis caused by a DNA virus that persists in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids.

14 Feb 2005

PAHO vaccines books wins major award

The Pan American Health Organization’s publication, Vaccines: Preventing Disease and Protecting Health, has won an award from the Association of American Publishers in the medical science category.

9 Feb 2005

Evolutionarily ancient enzyme-repair system used to identify type of DNA damage responsible for the onset of skin-tumor development

In a finding that broadens our insight into the cause of certain kinds of UV-induced skin cancer, researchers at Erasmus University Medical Center (Rotterdam, The Netherlands) have employed an evolutionarily ancient enzyme-repair system to identify the principal type of DNA damage responsible for the onset of skin-tumor development.

26 Jan 2005

Biopharmaceutical market generated revenues of USD 45.0 billion in 2004

New analysis from Frost & Sullivan, Strategic Analysis of the World Plant Molecular Farming Market, reveals that the biopharmaceutical market generated revenues of USD 45.0 billion in 2004. It is likely to reach USD 98.2 billion by 2011.

17 Jan 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Turning off cell suicide switch fails to stop prion damage

Researchers knew that prions, the misfolded proteins that cause mad cow disease and other brain disorders, were killing off a class of important brain cells in a transgenic mouse model. But when they found a way to rescue those cells, they were astonished to discover the mice still became sick.

21 Dec 2004

Cancer drug paclitaxel may reduce the adverse effects of Alzheimer's disease

In a preclinical efficacy trial, the cancer drug paclitaxel (Paxceed)–which exerts its effects by binding to and stabilizing microtubules inside cells–reduced the adverse effects of Alzheimer's disease (AD)-like pathology in a mouse model.

20 Dec 2004

Neurobiologists distinguish in unprecedented detail the patterns of brain activity

Using hairlike microelectrodes and computer analysis, neurobiologists at Duke University Medical Center have demonstrated that they can see the detailed instant-to-instant electrical "brainscape" of neural activity across a living brain.

8 Dec 2004

New clues in understanding why group A streptococci (GAS) has a range of bacterial afflictions in humans

Researchers have unlocked new clues in understanding why group A streptococci (GAS) has a range of bacterial afflictions in humans. One of the keys to this species of bacteria is its production of streptokinase (SK), an enzyme that activates plasminogen, the blood clot-dissolving protein in humans.

6 Dec 2004

Mad cow disease prions can be removed from blood

New research results released today confirm that infectious variant Creutzfeldt-Jakob Disease (vCJD) prions that cause the human form of "mad cow disease" can be removed from blood.

From Pall Corporation 3 Nov 2004

Scientists have uncovered a significant new link in the chain of immune system events through which estrogen prevents bone loss

Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.

29 Oct 2004

A new approach to controlling blood cholesterol levels may be a potential treatment for Alzheimer's disease

A new approach to controlling blood cholesterol levels that is already being investigated to prevent cardiovascular disease also may be a potential treatment for Alzheimer's disease.

13 Oct 2004

Edible vaccine for HIV AIDS

Scientists from Novosibirsk are engaged in the development of an unusual vaccine which, apart from being less expensive to produce, safe and painless to administer, is also edible.

22 Sep 2004

Vanilla may become a drug to treat sickle cell disease

In addition to its popular role in flavoring ice cream, fudge and cake frosting, vanilla may have a future use as a medicine. Recent laboratory research has strengthened the possibility that a form of vanilla may become a drug to treat sickle cell disease.

20 Sep 2004